摘要
目的观察地特胰岛素注射液联合瑞格列奈治疗高龄2型糖尿病的疗效和安全性。方法 选取32例口服降糖药疗效不佳的高龄糖尿病患者，给予地特胰岛素注射液每晚睡前1次，皮下注射，使空腹血糖达标（3.9-7.0mmol/L）；同时联合瑞格列奈，使餐后2小时血糖控制达标（4.4-10.0mmol/L）。治疗3个月后，观察患者空腹血糖、餐后2小时血糖、糖化血红蛋白及体质指数（BMI）变化。结果 与治疗前相比，患者空腹血糖、餐后2小时血糖、糖化血红蛋白均显著下降（P〈0.05）；BMI前后对照，差异无显著性（P〉0.05）。结论 地特胰岛素注射液联合瑞格列奈治疗2型糖尿病低血糖发生率低，对体重影响小，安全有效。
Objective Observe the curative effect and security on the treatment of oral medications with poor blood sugar control in type 2 diabetes combined with Detemir and Repaglinide. Method Select 32 cases of oral medications with bad curative effect of diabetes patients,given to have one subcutaneous Determir insulin injection every night before sleeping,adjusted the dose so as to makes the fasting blood glucose（FBG） control at the target（3. 9 ~7. 0mmol/L）;At the same time Rapaglinide orally given ,also adjusted the dose in order to get the control of post-prandial blood glucose 2 h（2hPBG） at the target （4. 4-10. 0mmol/L）. Three months after the treatment,observe these patients changes on FBG,2hPBG,HbA1c and BMI. Result Compare the results of the treatment after three months with those before the treatment：FBG, 2hPBG and HbA1c, were significantly decreased（P〈0. 05）;Signifi-cant difference before and after the treatment was not observed in BMI（P〉0. 05）. Conclusion The treatment of De-temir in combination with Repaglinide, which treats elderly type 2 diabetes patients for its less weight gain and safe-ty,is suitable to carry out in primary health care organizations.
出处
《中国临床医生杂志》
2014年第2期27-28,共2页
Chinese Journal For Clinicians
